Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22720838 | 0.88 | NR1H2 (0.41) | NR1H2ESR2NFKB1NFKB2RELA | |
| Acetic Acid SCHEMBL28215593 | 0.84 | SMN1; SMN2 (0.40) | NR1H2ESR2NFKB1NFKB2RELA | |
| SCHEMBL27037069 | 0.83 | ESR2 (0.36) | NR1H2ESR2ELANEMAPK1USP2 | |
| SCHEMBL28688256 | 0.78 | ESR2 (0.41) | NR1H2ESR2ELANEMAPK1BUB1 | |
| SCHEMBL17267601 | 0.75 | ESR2 (0.40) | NR1H2ESR2MAPK1MAPTUSP2 | |
| SCHEMBL28831819 | 0.74 | ESR2 (0.40) | NR1H2ESR2NFKB1NFKB2RELA | |
| SCHEMBL31482816 | 0.74 | ESR2 (0.37) | NR1H2ESR2ELANEMAPK1MAPT | |
| SCHEMBL4439029 | 0.74 | NR1H2 (0.42) | NR1H2ESR2ELANEMAPK1KDM4E | |
| SCHEMBL2600437 | 0.73 | SMN1; SMN2 (0.56) | NR1H2ESR2NFKB1NFKB2RELA | |
| SCHEMBL1838102 | 0.73 | PREP (0.37) | NR1H2ESR2ELANEMAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119574680-A | Mass spectrum detection method for N-heterocyclic ketone and/or N-heterocyclic chiral amino compound and application thereof | 北京衍微科技有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-118755684-A | Catalytic enzyme for producing chiral aromatic amine, N-heterocyclic amine and derivatives thereof with high optical purity, and preparation method and application thereof | 杭州微远生物科技有限公司 | 2024-10-11 | — | — | CN | claimed |
| CN-116042560-A | Mutant of recombinant aminotransferase and application thereof | 清华大学 | 2023-05-02 | — | — | CN | claimed |
| CN-119574680-A | Mass spectrum detection method for N-heterocyclic ketone and/or N-heterocyclic chiral amino compound and application thereof | 北京衍微科技有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-118791506-A | KRAS inhibitor compounds, pharmaceutical compositions thereof and uses thereof | 广东东阳光药业股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118755684-A | Catalytic enzyme for producing chiral aromatic amine, N-heterocyclic amine and derivatives thereof with high optical purity, and preparation method and application thereof | 杭州微远生物科技有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-116042560-A | Mutant of recombinant aminotransferase and application thereof | 清华大学 | 2023-05-02 | — | — | CN | disclosed |
| US-20110086860-A1 | COMPOUND | KIMURA TEIJI | 2011-04-14 | — | — | US | disclosed |
| US-7880009-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; (E)-N-biphenyl-3-ylmethyl-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)acrylamide for example; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-2261218-A2 | Process for preparing phenyl-, pyridinyl- or pyrimidinyl-substituted imidazoles | Eisai R&D Management Co., Ltd. (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-7687640-B2 | Cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7667041-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-12 | — | — | US | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086860-A1 | COMPOUND | ARRB1, NR3C2, ADRA2C | NR1H2 474/4885ESR2 670/4885NFKB1 3274/4885 |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | APP, PSEN1, BACE1 | NR1H2 1811/4885ESR2 1916/4885NFKB1 1284/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | NR1H2 619/4885ESR2 1892/4885NFKB1 2066/4885 |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | PSEN1, APP, BACE1 | NR1H2 2951/4885ESR2 3277/4885NFKB1 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.